Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)

Next Previous
Trial Profile

A Randomized, Open-label Study of Serplulimab Plus Chemotherapy (Carboplatin-Etoposide) in Comparison With Atezolizumab Plus Chemotherapy in Previously Untreated US Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (ASTRIDE)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Jul 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Etoposide (Primary) ; Serplulimab (Primary) ; Atezolizumab
  • Indications Small cell lung cancer
  • Focus Adverse reactions; Registrational
  • Acronyms ASTRIDE
  • Sponsors Shanghai Henlius Biotech

Most Recent Events

  • 20 Jul 2026 According to a Henlius Biopharmaceuticals media release, the results form this trial will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress will take place from October 23-7 in Madrid, Spain
  • 27 Apr 2026 According to a Henlius Biopharmaceuticals media release, Biologics License Application (BLA) is planned to be submitted to the FDA in 2026.
  • 22 Oct 2025 According to a Shanghai Henlius Biotech media release, enrolment of all 200 patients in this trial has been completed

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top